These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 7529526)

  • 1. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
    Marshall D; Pedley RB; Melton RG; Boden JA; Boden R; Begent RH
    Br J Cancer; 1995 Jan; 71(1):18-24. PubMed ID: 7529526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.
    Marshall D; Pedley RB; Boden JA; Boden R; Melton RG; Begent RH
    Br J Cancer; 1996 Mar; 73(5):565-72. PubMed ID: 8605088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
    Marshall D; Pedley RB; Boden JA; Boden R; Begent RH
    Br J Cancer; 1994 Mar; 69(3):502-7. PubMed ID: 8123481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.
    Govindan SV; Griffiths GL; Michel RB; Andrews PM; Goldenberg DM; Mattes MJ
    Cancer Biother Radiopharm; 2002 Jun; 17(3):307-16. PubMed ID: 12136523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
    Casey JL; King DJ; Chaplin LC; Haines AM; Pedley RB; Mountain A; Yarranton GT; Begent RH
    Br J Cancer; 1996 Nov; 74(9):1397-405. PubMed ID: 8912535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts.
    Vogel CA; Bischof-Delaloye A; Mach JP; Pèlegrin A; Hardman N; Delaloye B; Buchegger F
    Br J Cancer; 1993 Oct; 68(4):684-90. PubMed ID: 8398694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.
    Pedley RB; Boden JA; Boden R; Dale R; Begent RH
    Br J Cancer; 1993 Jul; 68(1):69-73. PubMed ID: 8318423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
    Pedley RB; Boden JA; Boden R; Begent RH; Turner A; Haines AM; King DJ
    Br J Cancer; 1994 Dec; 70(6):1126-30. PubMed ID: 7981064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of circulatory clearance of tumour-localising IgG and F(ab')2 for potential therapy studied in a CEA-producing xenograft model.
    Harwood PJ; Pedley RB; Boden J; Rogers GT
    Tumour Biol; 1987; 8(1):19-25. PubMed ID: 3602844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of unlabelled monoclonal antibodies on the biodistribution of 111In-labelled anti-prostate-specific acid phosphatase monoclonal antibodies in the mouse model.
    Peräalä-Heape M; Vihko P; Vihko R
    Anticancer Res; 1991; 11(3):1327-31. PubMed ID: 1888168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model.
    Sharma SK; Bagshawe KD; Burke PJ; Boden RW; Rogers GT
    Br J Cancer; 1990 May; 61(5):659-62. PubMed ID: 2337503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood and tissue kinetics of radiolabelled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy.
    Pimm MV; Andrew SM; Baldwin RW
    Nucl Med Commun; 1989 Aug; 10(8):585-93. PubMed ID: 2812641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
    Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
    Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
    Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in biodistribution of the anti-(carcinoembryonic antigen) murine monoclonal antibody CE-25, its F(ab')2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected.
    Westera G; Rülicke T; Smith A; Duewell S
    Cancer Immunol Immunother; 1994 Dec; 39(6):375-82. PubMed ID: 8001025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.
    Lane DM; Eagle KF; Begent RH; Hope-Stone LD; Green AJ; Casey JL; Keep PA; Kelly AM; Ledermann JA; Glaser MG
    Br J Cancer; 1994 Sep; 70(3):521-5. PubMed ID: 8080740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
    Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA
    Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.